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Independent Data Monitoring Committees (DMCs, DSMBs, DMECs) aim to protect the 
interests of trial participants.  The duty of care towards participants is paramount and should 
be untrammelled by conflicting interests.   
 
Good Clinical Practice (GCP) provides direction on composition and operation of DMCs[1, 
2].  ICH E9 states: “All staff involved in the conduct of the trial should remain blind to the 
results of… [interim] analyses, because of the possibility that their attitudes to the trial will be 
modified and cause changes in the characteristics of patients to be recruited or biases in 
treatment comparisons.”  The US Food and Drug Administration (FDA) and the European 
Medicines Agency (EMA) provided similar regulatory guidance.[3, 4]  Neither requires the 
statistician performing the interim analyses to be independent or different from those 
involved in trial management and performing the final analyses.  However the FDA[3] states: 
“the integrity of the trial may be best protected when the statisticians preparing unblinded 
data for the DMC are external to the sponsor and uninvolved in discussions regarding 
potential changes in trial design while the trial is ongoing.”  Industry routinely implements this 
FDA guidance, but this is rarely the case in publically funded trials. 
 
The risk of conflicts of interest in industry with the development of drugs is somewhat 
obvious, but conflicts may be less clear in academia.  Academics do however have an 
interest in the success of their trials, which may lead to career advancement.  Trial 
statisticians in UK and US government funded trials are often responsible for creating 
unblinded DMC reports and attending closed sections of meetings, undermining the principle 
of the committee being independent, with interim results from ongoing trials known by at 
least one of the management team.  Many statisticians working on academic trials do not 
perceive this to be bias and some are reluctant to rescind their informed status.  This is in 
breach of GCP. 
 
Whether the allocations are explicit or data are analysed blind (e.g. described as groups ‘A’ 
and ‘B’), the statistician knows the potential treatments.   It is our experience that they or 
DMC members will normally deduce the randomised allocation through the adverse event or 
outcome profiles.[5]  In a recent trial, blood concentrations were higher in one randomised 
group, resulting in adverse events.  The DMC clinicians identified the treatment groups, 
unblinding the trial statistician. 
 
When trial statisticians present interim results to the DMC, they cannot avoid contributing to 
the interpretation.  They are party to discussions between the independent DMC members 
and will exert influence despite being conflicted in discussions.  Further, when the trial 
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management group to which they belong considers changing some aspect of the trial, for 
example inclusion criteria or the definition of the primary outcome, the trial statistician cannot 
put aside their knowledge.  The statistician may know from the emerging data the 
implications for the trial.[6]  This occurred in a trial of two vasectomy techniques.[7]  Although 
the interim analyses were presented blinded, the DMC guessed the allocations, with the trial 
statistician party to this information.  The trial statistician noticed an interaction.  This was 
instrumental in stopping the trial despite the DMC recommending continuation.   
 
One of us was a member of a DMC where the trial statistician presented the interim results; 
however the timing of the primary outcome was not defined in the protocol or statistical 
analysis plan.  The primary analysis would thus be specified with knowledge of unfolding 
results, a clear source of bias.  The trial statistician did not address the ambiguity which was 
also not addressed by the Trial Management Group; the DMC member subsequently 
resigned.   
 
In 2005, the DAMOCLES group published a charter for DMCs.[8]  They did not give 
guidance on who should undertake interim analyses or present them to the DMC, merely 
documented what usually happened.[9]  Three alternative models were presented, including 
one where the statistician analysing data for the DMC would be semi-independent and a little 
removed from trial management.  This charter has been widely adopted in UK publicly 
funded trials despite its recommendations being out with GCP.  This may be because 
authors were employed by UK academic or research councils, which are not funded as 
generously as industry.  A completely independent statistician would increase costs.  
However many clinical trials units include two statisticians in their grant applications.  This 
would allow a compromise to involve (at least) two statisticians in all trials; one attending trial 
management meetings and performing the final analysis and the other performing the interim 
analyses, attending the DMC meetings as a non-voting member and confirming the final 
analysis.  The second statistician would forfeit any trial management responsibilities from the 
point of first interim analysis.[3, 10, 11]  A third independent, qualified and experienced 
statistician from a different centre would sit on the DMC as a voting member.  
 
Society has a duty of care towards those who participate in research.  Researchers have a 
responsibility to ensure they provide unbiased guidance to inform future care.  DMCs should 
be independent and use their position only to intervene with trial management when there 
are serious safety concerns, or where efficacy can be established unequivocally.  Properly 
constituted, independent DMCs should be established in all but the lowest risk trials. 
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